Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices

por Ebbers, Hans C., Chamberlain, Paul
Publicado 2016

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

por Ebbers, Hans C., Pieper, Burkhard, Issa, Amine, Addison, Janet, Freudensprung, Ulrich, Rezk, Mourad F.
Publicado 2019

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

por Barbier, Liese, Ebbers, Hans C., Declerck, Paul, Simoens, Steven, Vulto, Arnold G., Huys, Isabelle
Publicado 2020

An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review

por Hariprasad, Seenu M., Gale, Richard P., Weng, Christina Y., Ebbers, Hans C., Rezk, Mourad F., Tadayoni, Ramin
Publicado 2022

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals

por Ebbers, Hans C., Mantel-Teeuwisse, Aukje K., Sayed-Tabatabaei, Fakhredin A., Moors, Ellen H. M., Schellekens, Huub, Leufkens, Hubert G. M.
Publicado 2012

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized contro...

por Ebbers, Sander C., Braat, Arthur J. A. T., Moelker, Adriaan, Stokkel, Marcel P. M., Lam, Marnix G. E. H., Barentsz, Maarten W.
Publicado 2020

An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe

por Ebbers, Hans C., Langedijk, Joris, Bouvy, Jacoline C., Hoekman, Jarno, Boon, Wouter P. C., de Jong, Jean Philippe, De Bruin, Marie L.
Publicado 2015

Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres

por Ebbers, S. C., Kunnen, B., van Nierop, B. J., Bemelmans, J. L. M., Krijger, G. C., Lam, M. G. E. H., Braat, A. J. A. T.
Publicado 2020

Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study

por Ebbers, Sander C., Heimgartner, Muriël, Barentsz, Maarten W., van Leeuwaarde, Rachel S., van Treijen, Mark J. C., Lam, Marnix M. E. G., Braat, Arthur J. A. T.
Publicado 2021

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

por Ebbers, Hans C., Fehrmann, Bjørn, Ottosen, Mette, Hvorslev, Niels, Høier, Pia, Hwang, Jae-Woong, Chung, Jinhan, Lim, Hyoung Taek, Lee, Shinjung, Hong, Juyoung, Rezk, Mourad Farouk
Publicado 2020

Baseline Imaging Derived Predictive Factors of Response Following [(177)Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Bas...

por van der Sar, Esmée C. A., Kühr, Adinda J. S., Ebbers, Sander C., Henderson, Andrew M., de Keizer, Bart, Lam, Marnix G. E. H., Braat, Arthur J. A. T.
Publicado 2022

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide th...

por Ebbers, Sander C., Brabander, Tessa, Tesselaar, Margot E. T., Hofland, Johannes, Braat, Manon N. G. J. A., Wessels, Frank J., Barentsz, Maarten W., Lam, Marnix G. E. H., Braat, Arthur J. A. T.
Publicado 2022